Anthracyclines

Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

Retrieved on: 
Tuesday, August 3, 2021

The Company anticipates dosing the first patient in the trial in the fourth quarter of this year.

Key Points: 
  • The Company anticipates dosing the first patient in the trial in the fourth quarter of this year.
  • We eagerly await reaching each higher dose level in this trial, said Andrew Mazar, PhD, Monopars Chief Scientific Officer.
  • Camsirubicin is a novel analog of doxorubicin, and doxorubicin is known to work through a dose-dependent mechanism, where higher quantities yield more anti-cancer effect.
  • If successful in ASTS, there are 13 other potential cancer indications for camsirubicin where doxorubicin is already FDA-approved, said Chandler Robinson, MD, Monopars Chief Executive Officer.

Celsion GmbH Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer

Retrieved on: 
Thursday, July 1, 2021

LAWRENCEVILLE, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company, announces commencement of enrollment in Oxford Universitys Phase I PanDox study with ThermoDox in conjunction with Focused Ultrasound in patients with pancreatic cancer.

Key Points: 
  • LAWRENCEVILLE, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company, announces commencement of enrollment in Oxford Universitys Phase I PanDox study with ThermoDox in conjunction with Focused Ultrasound in patients with pancreatic cancer.
  • The primary endpoint of the two-arm 18-subject PanDox study is enhanced uptake of doxorubicin in pancreatic tumors using ThermoDox and Focused Ultrasound (FUS), compared to systemic delivery of free doxorubicin.
  • ThermoDox, a heat activated liposomal doxorubicin, will be administered intravenously in 12 patients with non-resectable pancreatic ductal adenocarcinoma (PDAC) and locally activated by focused ultrasound-mediated hyperthermia.
  • Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®

Retrieved on: 
Wednesday, June 23, 2021

LAWRENCEVILLE, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored development of ThermoDox, the Companys proprietary heat-activated liposomal encapsulation of doxorubicin.

Key Points: 
  • LAWRENCEVILLE, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored development of ThermoDox, the Companys proprietary heat-activated liposomal encapsulation of doxorubicin.
  • A clinical project at the National Institutes of Health to evaluate ThermoDox plus the chemotherapy drug mitomycin in bladder cancer.
  • Celsion GmbHs long-term objective is to seek partnerships that will maximize the potential of ThermoDox, ultimately providing value to the parent company.
  • Celsion also has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.

Global Liposomal Drug Delivery Devices Market 2020-2030: COVID-19 Impacts, Growth and Changes

Retrieved on: 
Thursday, February 4, 2021

Liposomal Drug Delivery Devices Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global liposomal drug delivery devices market.

Key Points: 
  • Liposomal Drug Delivery Devices Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global liposomal drug delivery devices market.
  • The liposomal drug delivery devices market consists of sales of liposomal drug delivery devices and related services by entities (organizations, sole traders, and partnerships) that manufacture liposomal drug delivery devices.
  • The liposomal drug delivery devices market covered in this report is segmented by type into liposomal doxorubicin; liposomal paclitaxel; liposomal amphotericin B; others.
  • Global Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
    4.2.

Global Liposomal Drug Delivery Devices Market 2020: Major Players are Fudan-Zhangjiang, Pacira, Johnson and Johnson, Gilead Sciences, Novartis, Luye Pharma, CSPC, Ipsen and Teva Pharma - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 3, 2021

Liposomal Drug Delivery Devices Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global liposomal drug delivery devices market.

Key Points: 
  • Liposomal Drug Delivery Devices Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global liposomal drug delivery devices market.
  • Major players in the liposomal drug delivery devices market are Fudan-Zhangjiang, Pacira, Johnson and Johnson, Gilead Sciences, Novartis, Luye Pharma, CSPC, Ipsen (Onivyde) and Teva Pharmaceutical.
  • The liposomal drug delivery devices market consists of sales of liposomal drug delivery devices and related services by entities (organizations, sole traders, and partnerships) that manufacture liposomal drug delivery devices.
  • The liposomal drug delivery devices market covered in this report is segmented by type into liposomal doxorubicin; liposomal paclitaxel; liposomal amphotericin B; others.

Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs

Retrieved on: 
Tuesday, December 22, 2020

The patent, which expands the Companys camsirubicin intellectual property portfolio, is expected to expire in 2038 not including any patent term extensions.

Key Points: 
  • The patent, which expands the Companys camsirubicin intellectual property portfolio, is expected to expire in 2038 not including any patent term extensions.
  • The analogs covered in this patent have been designed to retain the potentially favorable non-cardiotoxic chemical backbone of camsirubicin and the potent broad-spectrum antitumor activity of doxorubicin; further, preclinical evidence suggests that this new family of 2-pyrrilino camsirubicin analogs could be active in doxorubicin-resistant tumor cells.
  • This may enable us to address additional cancer types beyond those possible with camsirubicin, said Andrew Mazar, PhD, Monopars Chief Scientific Officer.
  • Monopar Therapeutics is a clinical-stage biopharmaceutical companyprimarilyfocused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.

Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference

Retrieved on: 
Thursday, December 3, 2020

"We are extremely encouraged by the strong pre-clinical efficacy demonstrated by the combination of Annamycin and Ara-C against AML," commented Walter Klemp, Chairman and CEO of Moleculin.

Key Points: 
  • "We are extremely encouraged by the strong pre-clinical efficacy demonstrated by the combination of Annamycin and Ara-C against AML," commented Walter Klemp, Chairman and CEO of Moleculin.
  • Substituting a currently used anthracycline such as doxorubicin with Annamycin would be a familiar and well-practiced treatment modality.
  • We look forward to further discussing the promise of this combination at the 62nd Annual Meeting & Exposition of the American Society for Hematology."
  • The Company believes these experiments support initiation for the clinical development of the combination of Annamycin and Ara-C in AML patients.

CELSION ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Celsion Corporation and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, October 30, 2020

Investors have until December 28, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until December 28, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Celsion is an integrated development clinical stage oncology drug company that focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer.
  • Celsions lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin that is in Phase III clinical development for treating primary liver cancer.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Cancer

Retrieved on: 
Wednesday, October 7, 2020

The study received Food and Drug Administration (FDA) authorization and was slated to initially enroll 268 subjects across both cohorts.

Key Points: 
  • The study received Food and Drug Administration (FDA) authorization and was slated to initially enroll 268 subjects across both cohorts.
  • CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases.
  • CytRx's most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc.
  • Other indications currently at registration-stage trials include BCG-unresponsive papillary bladder cancer, first- and second-line lung cancer, and metastatic pancreatic cancer.

Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases

Retrieved on: 
Thursday, June 25, 2020

This was once again confirmed by the data, as Annamycin accumulated in the lungs at nearly 6 times the level of doxorubicin.

Key Points: 
  • This was once again confirmed by the data, as Annamycin accumulated in the lungs at nearly 6 times the level of doxorubicin.
  • A greatly increased concentration of Annamycin in the lung, as compared to doxorubicin, leads to high drug efficacy in vivo in lung-localized tumor models.
  • Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition, such as WP1122.
  • Forward-looking statements in this press release include, without limitation, the ability of Annamycin to show safety and efficacy in patients with lung metastases.